NuraPlex U.S. launch
This article was originally published in The Tan Sheet
Executive Summary
Eight multi-nutrient supplements for cancer patients that help "optimize health" during radiation and chemotherapy will launch in U.S. in February under the NuraPlex brand, AustCancer announces Oct. 17. Products initially will be available through health care professionals; the firm currently is in negotiations with a supermarket retailer in the Northeast. AustCancer expects NuraPlex products to be cash-flow positive within 12 months of launch...
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.